Global estimates for the lifetime cost of managing HIV

Abstract

We conducted a systematic review (PROSPERO:CRD42020184490) using five databases from 1999-2019. Methods:Studies were included if they reported primary data on lifetime costs for people living with HIV. Two reviewers independently assessed the titles and abstracts, and data were extracted from full texts: lifetime cost, year of currency, country of currency, discount rate, time horizon, perspective, method used to estimate cost, and cost items included. Descriptive statistics were used to summarize the discounted lifetime costs (2019 USD). Results:Of 505 studies found, 260 full-texts were examined and 75 included. Fifty (67%) studies were from high-income, 22 (29%) from middle-income and 3 (4%) from low-income countries. Of 65 studies which reported study perspective, 45 (69%) were healthcare provider and the remainder were societal. The median lifetime costs for managing HIV differed according to: 1) country income level: $5,221 (IQR:2,978-11,177) for low-income to

Lifetime cost of HIV management in Australia: an economic model

“…This study adds to the global body of literature on estimating the lifetime cost of HIV management, providing a comparison to lifetime cost estimates in other countries and a reference for future Australian lifetime cost models for healthcare budgeting. 10 We also add to the international literature by underscoring the relatively high contribution of the cost of ART and thus the potential costsavings from using generic drugs. When multiplying the lifetime cost estimate by the estimated number of PLHIV in Australia (for the Australian population of PLHIV at the start of 2019), it would cost the government an estimated A $7.9 billion over the next 61 years.…”

“…In the past 20 years, only two estimates of the lifetime cost of HIV management in Australian adults have been published. 10 Gray et al estimated a lifetime cost of A$424 844 (discounted at 3.5%, 2015 A$), 11 and the study by Tilden et al reported a lifetime cost of A$146 300 (discounted at 5%, 2010 A$). 12 However, since the publication of these two estimates, Australia has made changes related to commonly used antiretroviral regimens (e.g.…”

Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine

“…In view of these obstacles, new global initiatives for HIV prevention are required to tackle the challenges and worldwide financial burden of this epidemic [157]. Ideally, a prophylactic HIV vaccine would be available, enabling global vaccination campaigns in the near future.…”

Barriers to accessing HIV pre‐exposure prophylaxis for Medicare‐ineligible people in Melbourne, Australia: analysis of patients attending the PrEPMe Clinic

“…In a high income country like Australia, the additional cost of providing universally subsidised PrEP care would likely be lower than treating preventable new HIV infections, with an estimated lifetime cost of more than US$350 000 per HIV infection diagnosis. 6 …”